Immunophenotype distinction between acute promyelocytic leukaemia and CD15− CD34− HLA‐DR− acute myeloid leukaemia with nucleophosmin mutations

Abstract excerpt

Acute promyelocytic leukaemia (APL) is a unique clinicobiologic entity that can be successfully treated with All-trans Retinoic Acid ATRA-based regimens. Some cases of acute myeloid leukaemia (AML) with nucleophosmin (NPM) mutations have an immunophenotype that is similar to APL. The objective of the study is to compare antigenic expression in a group of APL patients with that in AML patients with NPM mutations...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Lymphoma Diagnosis and Treatment
• Share to Retinoids in leukemia and cellular processes